Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer

January 8, 2009 updated by: CASI Pharmaceuticals, Inc.
The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana Cancer Pavilion, Indiana University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion:

  • Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural effusions, or Stage IV NSCLC or recurrent NSCLC
  • No previous chemotherapy for NSCLC
  • Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT greater than 1 cm in diameter
  • Specified lab parameters
  • Life expectancy of at least 12 weeks
  • ECOG performance status of 0 or 1
  • Understand requirements of study
  • Agree to use effective contraceptive methods

Exclusion:

  • Have CNS metastases
  • Have any active cancer in addition ot NSCLC
  • Participated in clinical trial involving conventional or investigational drugs within previous 4 weeks
  • Have any contraindication to paclitaxel or carboplatin
  • Have had Grade 3 or greater peripheral neuropathies
  • Be pregnant or lactating
  • Have a history of myocardial infarction or angina pectoris/angina in the last 6 months
  • Have had significant (30 mL or more) hemoptysis with the past 3 months
  • Have an active infection
  • Have a history of bleeding diathesis, hypercoagulable condition, or an active bleeding disorder
  • Be receiving concurrent treatment with therapeutic doses of heparin or coumadin
  • Have had major surgery within 4 weeks of stating therapy
  • Have additional uncontrolled serious medical conditions or psychiatric illness
  • Received rhAngiostatin in other clinical protocols

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

CASI Pharmaceuticals, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Completion

December 1, 2004

Study Registration Dates

First Submitted

November 13, 2002

First Submitted That Met QC Criteria

November 14, 2002

First Posted (Estimate)

November 15, 2002

Study Record Updates

Last Update Posted (Estimate)

January 9, 2009

Last Update Submitted That Met QC Criteria

January 8, 2009

Last Verified

January 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ANG-CL-004

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Clinical Trials on carboplatin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe